IDXG · Interpace Biosciences, Inc.

Interpace Biosciences' Q1 2026 results highlight the benefits of its transition to a thyroid-only diagnostics model, with revenue of $9.0 million reflecting a 14% increase from the pro forma prior year quarter after excluding discontinued PancraGEN operations. Thyroid revenue specifically grew 12% year-over-year, driven by 10% higher test volume, 3% higher average revenue per test, 9% higher average volume per account, and a 5% increase in the number of accounts. Gross margin expanded to 65% from 59% pro forma, reflecting operational efficiencies including 21% faster turnaround time and 6% lower days sales outstanding. Adjusted EBITDA rose to $1.6 million (17% margin) from $0.8 million pro forma, with operating income of $1.1 million (12% margin). Management attributes this to the strength of the ThyGeNEXT and ThyraMIR v2 platform, consistent commercial execution, and investments in laboratory automation and AI productivity on a debt-free balance sheet, enabling scaling without headcount growth. The company reaffirmed its full-year 2026 guidance for approximately 16% thyroid revenue growth, emphasizing deeper adoption in existing accounts, account base expansion, and productivity gains. Cash collections reached $8.7 million, supporting a cash position of $2.6 million at quarter-end, with positive operating cash flow of $0.3 million.